{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-124592","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2022-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.313964+00:00","generated_at":"2026-06-21T09:44:28.370990+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Liquidia collaborates with Sandoz and Mainbridge to develop new pump for treprostinil; promotion deal extended to 2032","bullets":["Development agreement with Mainbridge to create new subcutaneous pump for treprostinil injection, targeting 510(k) submission in 2023.","Sandoz and Liquidia will equally split development costs; Mainbridge to perform all development, validation, and testing.","Promotion agreement for Treprostinil Injection extended by five years, now through December 31, 2032.","New pump aims to reduce single-source dependence on existing CADD-MS 3 system for PAH patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-124592","json":"https://secwatch.observer/filing/0001104659-22-124592.json","markdown":"https://secwatch.observer/filing/0001104659-22-124592.md","text":"https://secwatch.observer/filing/0001104659-22-124592.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465922124592/0001104659-22-124592-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465922124592/tm2231990d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T09:44:28.370990+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"35532c9ac89cf2e85abe9ea097f9020f7a555f61","claim":"Liquidia Corp entered into Pump Development Agreement with Mainbridge Health Partners, LLC and Sandoz Inc. (effective 2022-12-01).","evidence_excerpt":"On December 1, 2022, Liquidia PAH, LLC, a Delaware limited liability company (“Liquidia PAH”), a wholly-owned subsidiary of Liquidia Corporation, a Delaware corporation (the “Company”), entered into a Device Development and Supply Agreement (the “Pump Development Agreement”) with Mainbridge Health Partners, LLC (“Mainbridge”) and Sandoz Inc. (“Sandoz”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465922124592/0001104659-22-124592-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Mainbridge Health Partners, LLC and Sandoz Inc."},{"label":"Effective","value":"2022-12-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}